This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merrimack Initiates Phase 1 Clinical Study Of MM-398 In Combination With Cyclophosphamide For Pediatric Solid Tumors

CAMBRIDGE, Mass., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 dose-escalating clinical study of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan that is designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors.

"Our preclinical research suggests that MM-398 accumulates particularly well in Ewing's sarcoma tumors," said Jonathan Fitzgerald, PhD, MM-398 Senior Director at Merrimack.

Preclinical research indicates that MM-398 administration results in delivery to the tumor of larger quantities of chemotherapy that are sustained for longer time periods compared with conventional chemotherapy administration. These effects may be applicable across other types of pediatric solid tumors. The most common forms of pediatric solid tumors include Ewing's sarcoma, rhabdomyosarcoma, neuroblastoma, and osteosarcoma.

"We are encouraged by the sensitivity of Ewing's sarcoma tumors to MM-398 that has been demonstrated in the laboratory setting. We are hopeful that the clinical results will mirror what we have seen in the preclinical studies," said C Patrick Reynolds, MD, PhD, Director of the Texas Tech University Health Sciences Center School of Medicine Cancer Center and of the South Plains Oncology Consortium.

This Phase 1 study will assess the safety of MM-398 in combination with cyclophosphamide in patients with recurrent or refractory pediatric solid tumors and will seek to determine the recommended Phase 2 dose. The trial will be sponsored by the South Plains Oncology Consortium and will be executed by participating institutions. Approximately 40 patients from 1 to 21 years old are expected to be enrolled. The first patient was dosed at the University of Texas Southwestern Medical Center.

About Ewing's Sarcoma

Ewing's sarcoma is an aggressive bone cancer primarily affecting children and adolescents, and is caused by the activation of the EWS gene due to a translocation between chromosomes 11 and 22. 1 There is currently no known risk factor or prevention for this disease. 2 Treatment includes multidrug chemotherapy and surgical resection, with radiation when necessary. 3 Metastatic Ewing's sarcoma is often seen at the time of diagnosis, and occurs in approximately 25% of patients. 4 While the outlook for patients with localized tumors is encouraging, with a five-year survival rate of approximately 60%-70%, outcomes for patients with metastatic tumors remain poor, with a five-year survival rate of approximately 20-30%. 5

About MM-398

MM-398 is a stable nanoliposomal irinotecan, designed to optimize the delivery of irinotecan by extending the duration of circulation in the body and preferentially activating the drug within the tumor to achieve higher levels of the active cytotoxic, SN-38. MM-398 is being evaluated in several clinical trials including a Phase 3 study in metastatic pancreatic cancer, a Phase 2 study in patients with metastatic colorectal cancer and a Phase 1 cross indication translational study. MM-398 is not approved for any indication by the FDA or any other regulatory agency.  Under a 2011 agreement with PharmaEngine, Inc. (Taipei, Taiwan), Merrimack consolidated the worldwide development and commercialization rights to MM-398, with the exception of commercialization rights in Taiwan which are held by PharmaEngine, Inc.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,051.73 -48.45 -0.28%
S&P 500 1,973.63 -4.59 -0.23%
NASDAQ 4,424.7040 -7.4420 -0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs